Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in Kuwait.
Campus
Campus

Compelling trial results: CRS with nasal polyps

The SINUS trial program studied the effects of Dupixent in patients with CRS with nasal polyps. Watch leaders in the field with firsthand experience in these trials as they take you through results that left them “overwhelmed.”1

The SINUS trial program showed that Dupixent provides rapid, sustained control, with improvements in nasal congestion, polyp burden, and sense of smell, as well as reduced patient need for revision surgery or systemic steroids.1,2

References

  1. DUPIXENT Summary of Product Characteristics, 2022.
  2. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebocontrolled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650. doi:10.1016/S0140-6736(19)31881-1
Related articles
Hear from an expert on Identifying Patients who are appropriate candidates for Biologic treatment
  • Nasal Polyps

Hear from an expert on Identifying Patients who are appropriate candidates for Biologic treatment

Read article
You can imagine more than 90% of CRSwNP patients losses their ability's of smell
  • Nasal Polyps

You can imagine more than 90% of CRSwNP patients losses their ability's of smell

Read article
“Smell—we call it the Cinderella of the senses
  • Nasal Polyps

“Smell—we call it the Cinderella of the senses"

Read article
MAT-BH-2201025/V1/FEB2023